Garrido A, Brunet S, Calabuig M, et al. Final results of the CETLAM LAM-203 trial fort he treatment of primary AML up tot the age of 70. EHA 2017, abstract S790.
GENEr8-1: resultaten 2 jaar na valoctocogene roxaparvovec bij hemofilie A
mei 2023 | Benigne hematologie